[imark3000]

http://ezinearticles.com/?The-Facts-...Disease&id=240
Any thoughts on this?

[soccertese]

Originally Posted by imark3000

http://ezinearticles.com/?The-Facts-...Disease&id=240
Any thoughts on this?

your link didn't come up but assume it was pushing glutathione
http://www.parkinson.org/NationalPar...dcba48b6cb.pdf

What’s Hot in Parkinson’s Disease?
July 2009
Glutathione Fails to Demonstrate Significant Improvement in
Parkinson’s Disease Symptoms in a Recently Published Trial
Michael S. Okun, M.D.
National Medical Director, National Parkinson Foundation
Dr. Robert Hauser and colleagues at the National Parkinson Foundation (NPF)
Center of Excellence at the University of South Florida recently put a highly
controversial drug of interest in Parkinson’s disease to the test. They carefully
performed the first randomized double-blind, placebo-controlled clinical trial of
intravenous glutathione therapy in twenty one Parkinson’s disease patients. The
therapy was well tolerated but there was no significant improvement in any
outcome variable.
The National Parkinson Foundation has for many years received a large number
of information requests on whether intravenous glutathione therapy works in any
positive way for Parkinson’s disease. Glutathione acts as an antioxidant, and
has been found to be reduced in the brains of patients with Parkinson’s disease.
Some doctors have chosen to offer a fee for infusion of glutathione service. It is
important for patients to be aware of several important facts about glutathione
therapy: first, there is a lack of evidence it actually works; second, the therapy
requires an intravenous line which has both short and long term risks; and finally,
insurance does not cover the costs of this therapy.
There is a clear message for patients and families in the Parkinson’s disease
community regarding this drug. At this time there exists no compelling evidence
that intravenous glutathione results in any meaningful clinical improvement in
Parkinson’s disease patients. Patients should beware of any medical practices
offering a fee for glutathione treatment of Parkinson’s disease.
The Hauser article appeared in the journal, Movement Disorders:
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Mov Disord.
Randomized, double-blind, pilot evaluation of intravenous glutathione in
Parkinson's disease. 2009 May 15;24(7):979-83.
*A letter to the editor of Movement Disorders concerning the appropriate
interpretation of the results for patients has been submitted by Dr.’s Jankovic
(Baylor), Lang (Toronto Western), and Okun (University of Florida

[imark3000]

Alterations in glutathione levels in Parkinson's disease and otherneurodegenerative disorders affecting basal ganglia
Jeswinder Sian BSc1, David T. Dexter PhD1, Andrew J. Lees FRCP2, Susan Daniel MRCPath2, Yves Agid MD, PhD3, France Javoy-Agid PhD3, Peter Jenner DSc1,*, C. David Marsden FRS2Article first published online: 8 OCT 2004
Abstract
Reduced glutathione (GSH) and oxidized glutathione (GSSG) levels were measured in various brain areas (substantia nigra, putamen, caudate nucleus, globus pallidus, and cerebral cortex) from patients dying with Parkinson's disease, progressive supranuclear palsy, multiple-system atrophy, and Huntington's disease and from control subjects with no neuropathological changes in substantia nigra. GSH levels were reduced in substantia nigra in Parkinson's disease patients (40% compared to control subjects) and GSSG levels were marginally (29%) but insignificantly elevated; there were no changes in other brain areas. The only significant change in multiple-system atrophy was an increase of GSH (196%) coupled with a reduction of GSSG (60%) in the globus pallidus. The only change in progressive supranuclear palsy was a reduced level of GSH in the caudate nucleus (51%). The only change in Huntington's disease was a reduction of GSSG in the caudate nucleus (50%). Despite profound nigral cell loss in the substantia nigra in Parkinson's disease, multiple-system atrophy, and progressive supranuclear palsy, the level of GSH in the substantia nigra was significantly reduced only in Parkinson's disease. This suggests that the change in GSH in Parkinson's disease is not solely due to nigral cell death, or entirely explained by drug therapy, for multiple-system atrophy patients were also treated with levodopa. The altered GSH/GSSG ratio in the substantia nigra in Parkinson's disease is consistent with the concept of oxidative stress as a major component in the pathogenesis of nigral cell death in Parkinson's disease.

[Catma]

In 2009 I had lipid exchange IV's every two weeks for 7 months or so, which included glutathione. Very costly and helped a little for one or two days before wearing off.

I've been reading that there is a stabilized form called acetyl glutathione that supposedly does not break down in digestion. I tracked some down and am trying it. The one I found is very expensive and comes in 100 mg capsules. With PD I hunch I'll need a lot to have any effect.

Has anyone else tried this?

I wonder if PD affects our ability to make our own glutathione? We need to take the precursors. One is NON-denatured whey protein. I found some at nutrabio.com quite reasonable. I've used both of their whey products and like both. I can't really tell if I'm making more glutathione or not. I stll have tremors. At least I'm getting some good protein!!

I like Dr Mark Hyman's YouTube video on glutathione.

Originally Posted by Catma

I like Dr Mark Hyman's YouTube video on glutathione.

I learned a lot from it too. Thanx for referencing it.